Solutions

Toxicity evaluation is crucial and is expensive in many countries when it comes to genotoxicity. The clinical development in the later stages happens to be one of the reasons that costs go out of hand. However, Stellixir Biotech has made significant strides in genotoxicity testing in order to identify compounds that may manifest genotoxic liabilities early in the drug discovery stages. We provide affordable drug candidate assessment packages. Our clients can order gent tox assays individually for their study, pick a selection of assays, or combine certain assays for in vitro toxicology services.

Vital Information Regarding Gene-Tox Assays:

• When conducting assays, we require a small amount of compound
• Rapid turnaround time
• AMES MPF assay using Xenometrix AG - ANIARA microplate kit method (OECD 471)
• In vitro micronucleus assay using CHO, CHL, A549 cell lines and human PBMCs including cytotoxicity assessment on high content screening (HCS) platform (OECD 487)
• In vitro chromosomal aberration assay using CHO cell line and human PBMCs including cytotoxicity assessment (OECD 473)
• Mammalian cell gene mutation assay: MLA (L5178YTk+/- cell line) and HPRT (CHO-K1 cell line) mutations (OECD 490/476)
• In vitro comet assay using PBMC, CHO, CHL test systems on HCS platform
• H2AX double strand DNA damage response assay using A549, HepG2 and BEAS-2B cell lines on HCS platform

The in vitro micronucleus assay uses automated scoring by High Content Analysis (HCA) versus manual scoring.